China's medical products administrator approved Luye Pharma Group's (HKG:2186) LY03020 anti-schizophrenic drug for clinical trials in the country, according to a Monday filing with the Hong Kong Stock Exchange.
The drug is also indicated for the treatment of Alzheimer's disease psychosis, which causes hallucinations and delusions, the filing said.
Shares rose 5% in Hong Kong during Tuesday's afternoon trading.
Price (HKD): $2.86, Change: $+0.13, Percent Change: +4.76%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments